Thrombophilia in pregnancy: Maternal and fetal implications

Current Women's Health Reviews

Volumn 2, Issue 1, 2006, Pages 51-59

  James, Andra H ^a   Brancazio, Leo R ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Miscarriage; Pregnancy; Thrombophilia; Thrombosis; Venous thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; ENOXAPARIN; HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CHILDBIRTH; DEEP VEIN THROMBOSIS; FEMALE; FETUS OUTCOME; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; LUNG EMBOLISM; MATERNAL WELFARE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOLUTIO PLACENTAE; STILLBIRTH; STROKE; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 33746116449     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340406775486265     Document Type: Review

References (117)

1. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101(1):6-14.
2. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the Incidence of Venous Thromboembolism during Pregnancy or Postpartum: A 30-Year Population-Based Study. Ann Intern Med 2005; 143(10): 697-706.
3. James AH, Brancazio LR, Jamison MG, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors and mortality. Am J Obstet Gynecol 2006: In press.
4. James A, Jamison M, Swamy G, Myers E. Acute myocardial infarction during pregnancy and postpartum. Am J Obstet Gynecol 2004; 191(6): 89S.
5. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106(3): 509-516.
6. Bergqvist A, Bergqvist D, Lindhagen A, Matzsch T. Late symptoms after pregnancy-related deep vein thrombosis. Br J Obstet Gynaecol 1990; 97(4): 338-341.
7. Ulander VM, Lehtola A, Kaaja R. Long-term outcome of deep venous thrombosis during pregnancy treated with unfractionated heparin or low molecular weight heparin. Thromb Res 2003; 111(4-5): 239-242.
8. Rosfors S, Noren A, Hjertberg R., Persson L, Lillthors K, Torngren S. A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg 2001; 22(5): 448-455.
9. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance - United States, 1991-1999. MMWR Surveill Summ 2003; 52(2): 1-8.
10. Lewis G, Drife J. Why mothers die 2000-2002 - report on confidential enquiries into maternal deaths in the United Kingdom. London: Royal College of Obstetricians and Gynaecologists 2004; 6th report.
11. Maternal mortality in 2000: estimates developed by WHO, UNICEF and UNFPA: WHO 2004.
12. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998; 79(1): 69-73.
13. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16(6): 742-748.
14. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63(2): 319-320.
15. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14(2): 127-141.
16. Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta - a delicate balance. N Engl J Med 2002; 347(1): 57-59.
17. Bulletin AP. Management of early recurrent pregnancy loss. Washington, DC: American College of Obstetricians and Gynecologists 2001.
18. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99(2): 333-341.
19. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343(20): 1439-1444.
20. Branch DW, Rodgers GM. Recombinant activated factor VII: a new weapon in the fight against hemorrhage. Obstet Gynecol 2003; 101(6): 1155-1156.
21. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103(10): 3695-3699. Epub 2004 Jan 3622.
22. Karsan A, Harlan J. The blood vessel wall. In: al RHe, ed. Hematology: Basic Principles and Practice. 3rd ed. NYC: Churchill Livingstone 2000; 1770-1782.
23. Lopez J, Berndt C. The GPIb-IX-V complex. In: Michelson A, ed. Platelets. NYC: Academic Press 2002; 85-104.
24. Hato T, Ginsberg M, Shattil S. Integren alpha IIb beta 3. In: Michelson A, ed. Platelets. NYC: Academic Press 2002; 105-116.
25. Mann KG. Thrombin formation. Chest 2003; 124(3 Suppl): 4S-10S.
26. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33(5): 357-421.
27. Esmon C. Regulatory mechanisms in hemostasis: natural anticoagulants. In: al RHe, ed. Hematology: Basic Principles and Practice. 3rd ed. New York: Churchill Livingstone 2000; 1814-1824.
28. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003; 1(7): 1515-1524.
29. Esmon CT. The protein C pathway. Chest 2003; 124(3 Suppl): 26S-32S.
30. Nesheim M. Thrombin and fibrinolysis. Chest 2003; 124(3 Suppl): 33S-39S.
31. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52(2): 176-182.
32. Sanchez-Luceros A, Meschengieser SS, Marchese C, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14(7): 647-651.
33. Wickstrom K, Edelstam G, Lowbeer CH, Hansson LO, Siegbahn A. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64(1): 31-40.
34. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16(2): 153-168.
35. Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80(1): 132-137.
36. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29(2): 125-130.
37. Sie P, Caron C, Azam J, et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII: C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121(6): 897-903.
38. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95(5): 1517-1532.
39. Dahlback B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Paper presented at: Proc Natl Acad Sci USA 1993.
40. Dahlback B. The discovery of activated protein C resistance. J Thromb Haemost 2003; 1(1): 3-9.
41. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130(8): 643-650.
42. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369(6475): 64-67.
43. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344(16): 1222-1231.
44. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88(10): 3698-3703.
45. Miner SE, Evrovski J, Cole DE. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem 1997; 30(3): 189-201.
46. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93(1): 7-9.
47. Barisic I, Clementi M, Hausler M, Gjergja R, Kern J, Stoll C. Evaluation of prenatal ultrasound diagnosis of fetal abdominal wall defects by 19 European registries. Ultrasound Obstet Gynecol 2001; 18(4): 309-316.
48. Ballem P. Acquired thrombophilia in pregnancy. Semin Thromb Hemost 1998; 24(Suppl 1): 41-47.
49. Girling J, de Swiet M. Acquired thrombophilia. Baillieres Clin Obstet Gynaecol 1997; 11(3):447-462.
50. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101 (6): 1333-1344.
51. di Simone N, Meroni PL, de Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43(1): 140-150.
52. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112(11): 1644-1654.
53. Gris JC, Perneger TV, Quere I, et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 2003; 102(10): 3504-3513. Epub 2003 Jul 3517.
54. de Groot PG, Derksen RH. The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Curr Opin Infect Dis 2005; 18(3): 205-210.
55. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342(6): 374-380.
56. Rosendaal FR, Koster T, Vandenbroueke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85(6): 1504-1508.
57. McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 2000; 107(4): 565-569.
58. Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 1998; 10(2): 135-144.
59. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157(18): 2101-2108.
60. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001; 44(6): 1466-1467.
61. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005; 193(1): 216-219.
62. Dilley A, Austin H, El-Jamil M, et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000; 183(5): 1271-1277.
63. Dekker GA, de Vries JI, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173(4): 1042-1048.
64. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348(9032): 913-916.
65. Prochazka M, Happach C, Marsal K, Dahlback B, Lindqvist PG. Factor V Leiden in pregnancies complicated by placental abruption. BJOG 2003; 110(5): 462-466.
66. Martinelli P, Grandone E, Colaizzo D, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 2001; 86(4): 428-431.
67. McCowan LM, Craigie S, Taylor RS, Ward C, McLintock C, North RA. Inherited thrombophilias are not increased in "idiopathic" small-for-gestational-age pregnancies. Am J Obstet Gynecol 2003; 188(4): 981-985.
68. Infante-Rivard C, Rivard GE, Yotov WV, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347(1): 19-25.
69. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005; 192(3): 694-708.
70. Glueck CJ, Kupfermine MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001; 97(1): 44-48.
71. Hakli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S. Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 2003; 7(3): 265-268.
72. Pegoraro RJ, Hira B, Rom L, Moodley J. Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia. Acta Obstet Gynecol Scand 2003; 82(4): 313-317.
73. Sofi F, Cesari F, Fedi S, Abbate R, Gensini GF. Protein Z: "light and shade" of a new thrombotic factor. Clin Lab 2004; 50(11-12): 647-652.
74. Han X, Fiehler R, Broze GJ, Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96(9): 3049-3055.
75. Paidas MJ, Ku DH, Lee MJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005; 3(3): 497-501.
76. Gris JC, Quere I, Dechaud H, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 2002; 99(7): 2606-2608.
77. Gris JC, Amadio C, Mercier E, et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 2003; 101(12): 4850-4852. Epub 2003 Mar 4856.
78. Rai R, Regan L, Clifford K, et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10(8): 2001-2005.
79. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lopus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161(2): 369-373.
80. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100(10): 909-913.
81. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361(9361): 901-908.
82. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004; 164(5): 558-563.
83. Reznikoff-Etievan MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG 2001; 108(12): 1251-1254.
84. Balasch J, Reverter JC, Fabregues F, et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12(5): 1094-1097.
85. Rai R, Shlebak A, Cohen H, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16(5): 961-965.
86. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77(5): 822-824.
87. Hashimoto K, Shizusawa Y, Shimoya K, et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod 1999; 14(7): 1872-1874.
88. Holmes ZR, Regan L, Chilcott I, Cohen H. The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss. Br J Haematol 1999; 105(1): 98-101.
89. Pickering W, Marriott K, Regan L. G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. Clin Appl Thromb Hemost 2001; 7(1): 25-28.
90. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 1991; 325(15): 1063-1066.
91. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 627S-644S.
92. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314(7076): 253-257.
93. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183(4): 1008-1012.
94. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100(3): 408-413.
95. Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179(5): 1324-1328.
96. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87(5): 791-795.
97. de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104(11): 1248-1254.
98. Goddijn-Wessel TA, Wouters MG, van de Molen EF, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996; 66(1): 23-29.
99. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998; 179(6 Pt 1): 1565-1567.
100. van der Spuy ZK, Bird AR, Lindow SW, Bruce C. The prevalence of antiphospholipid antibodies in women with reproductive failure or major abruptio placentae. S Afr Med J 1993; 83(5): 319-321.
101. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost 1999; 81(6): 891-899.
102. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340(1): 9-13.
103. Rothbart H, Ohel G, Younis J, Lanir N, Brenner B. High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death. J Matern Fetal Med 1999; 8(5): 228-230.
104. Leeda M, Riyazi N, de Vries JI, Jakobs C, van Geijn HP, Dekker GA. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol 1998; 179(1): 135-139.
105. Chikosi AD, Moodley J, Pegoraro RJ, Lanning PA, Rom L. 5,10 methylenetetrahydrofolate reductase polymorphism in black South African women with pre-eclampsia. Br J Obstet Gynaecol 1999; 106(11): 1219-1220.
106. Dizon-Townson D, Nelson L, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175(4 Pt 1): 902-905.
107. Grandone E, Margaglione M, Colaizzo D, et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999; 81(3): 349-352.
108. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998; 92(3): 457-460.
109. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176(2): 457-460.
110. Nagy B, Toth T, Rigo J, Jr., Karadi I, Romics L, Papp Z. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clin Genet 1998; 53(6): 478-481.
111. O'Shaughnessy KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999; 33(6): 1338-1341.
112. van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180(5): 1146-1150.
113. Horstkotte D. Prosthetic valves or tissue valves - a vote for mechanical prostheses. Z Kardiol 1985; 74 (Suppl 6): 19-37.
114. De Groot CJ, Bloemenkamp KW, Duvekot EJ, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999; 181(4): 975-980.
115. Mello G, Parretti E, Martini E, et al. Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis 1999; 29(4): 197-203.
116. Powers RW, Minich LA, Lykins DL, Ness RB, Crombleholme WR, Roberts JM. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Investig 1999; 6(2): 74-79.
117. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methyleneterahydrofolate reductase polymorphism and preeclampsia. J Med Genet 1997; 34(6): 525-526.